Metacrine (MTCR)

Company Profile

Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. The Company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH. MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being evaluated in a 16-week monotherapy trial in patients with NASH.

Company profile

Ticker

MTCR

Exchange

Website

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

SEC CIK

0001634379

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

IRS number

472297384

MTCR stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Departure of Directors or Certain Officers

3 Feb 23

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Departure of Directors or Certain Officers

24 Jan 23

8-K

Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement

23 Dec 22

DEFA14A

Additional proxy soliciting materials

14 Dec 22

425

Business combination disclosure

14 Nov 22

8-K

Metacrine Reports Third-quarter 2022 Results

14 Nov 22

Proxy related to merger

10 Nov 22

Latest ownership filings

View all

SC 13G/A

BML Investment Partners, L.P.

Braden Michael Leonard

21 Dec 22

SC 13G

TANG CAPITAL PARTNERS LP

19 Dec 22

SC 13D

BML Investment Partners, L.P.

8 Dec 22

Braden Michael Leonard

9 Nov 22

Braden Michael Leonard

31 Oct 22

SC 13G/A

BML Investment Partners, L.P.

27 Oct 22

Braden Michael Leonard

26 Oct 22

Financial summary

Financial statements Chart MTCR financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	52.75 mm	52.75 mm	52.75 mm	52.75 mm	52.75 mm	52.75 mm
Cash burn (monthly)	(no burn)	(no burn)	1.72 mm	3.04 mm	932.00 k	3.02 mm
Cash used (since last report)	n/a	n/a	7.49 mm	13.24 mm	4.05 mm	13.13 mm
Cash remaining	n/a	n/a	45.27 mm	39.51 mm	48.70 mm	39.63 mm
Runway (months of cash)	n/a	n/a	26.3	13.0	52.3	13.1

Beta Read what these cash burn values mean

Financial data from Metacrine earnings reports.

Institutional ownership, Q3 2022

MTCR institutional ownership history Ownership history

37.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	29	31	-6.5%
Opened positions	4	2	+100.0%
Closed positions	6	7	-14.3%
Increased positions	5	6	-16.7%
Reduced positions	4	8	-50.0%

13F shares	Current	Prev Q	Change
Total value	50.94 mm	50.19 mm	+1.5%
Total shares	16.08 mm	14.34 mm	+12.1%
Total puts	0.00	0.00
Total calls	0.00	90.70 k	EXIT
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Arch Venture	2.94 mm	$1.43 mm	0.0%
ARCH Venture Fund VIII	2.94 mm	$23.11 mm	0.0%
Polaris Partners VII	2.89 mm	$22.75 mm	0.0%
Tang Capital Management	1.72 mm	$833.00 k	NEW
BML Investment Partners	1.60 mm	$744.00 k	0.0%
Artal	924.90 k	$449.00 k	0.0%
ARE Alexandria Real Estate Equities	784.35 k	$529.00 k	0.0%
Renaissance Technologies	579.54 k	$281.00 k	-1.6%
Tudor Investment Corp Et Al	349.10 k	$169.00 k	NEW
Vanguard	254.49 k	$123.00 k	-43.2%

Largest transactions	Shares	Bought/sold	Change
Tang Capital Management	1.72 mm	+1.72 mm	NEW
Tudor Investment Corp Et Al	349.10 k	+349.10 k	NEW
Pura Vida Investments	0.00	-198.23 k	EXIT
Vanguard	254.49 k	-193.93 k	-43.2%
CSS	169.34 k	+169.34 k	NEW
Crestline Management	0.00	-158.66 k	EXIT
Citadel Advisors	136.61 k	+136.61 k	NEW
STT State Street	0.00	-72.19 k	EXIT
UBS UBS Group AG - Registered Shares	42.65 k	+32.08 k	+303.4%
Virtu Financial	0.00	-28.47 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

MTCR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
26 Jan 23	Preston Klassen	Common Stock	Sell	Dispose S	No	No	0.4132	380,605	157.27 k	541,905
26 Jan 23	Michael York	Common Stock	Sell	Dispose S	No	No	0.4141	107,054	44.33 k	103,499
21 Dec 22	Braden Michael Leonard	Common Stock	Buy	Acquire P	Yes	No	0.4	120,099	48.04 k	6,160,570
20 Dec 22	Braden Michael Leonard	Common Stock	Buy	Acquire P	Yes	No	0.3791	50,122	19.00 k	6,040,471
19 Dec 22	Braden Michael Leonard	Common Stock	Buy	Acquire P	Yes	No	0.4	101,384	40.55 k	5,990,349
9 Nov 22	Braden Michael Leonard	Common Stock	Buy	Acquire P	Yes	No	0.39	39,816	15.53 k	5,888,965
8 Nov 22	Braden Michael Leonard	Common Stock	Buy	Acquire P	Yes	No	0.4	500	200.00	5,849,149
7 Nov 22	Braden Michael Leonard	Common Stock	Buy	Acquire P	Yes	No	0.4223	123,954	52.35 k	5,848,649
28 Oct 22	Braden Michael Leonard	Common Stock	Buy	Acquire P	Yes	No	0.3998	45,022	18.00 k	5,724,695
27 Oct 22	Braden Michael Leonard	Common Stock	Buy	Acquire P	Yes	No	0.39	767,507	299.33 k	5,679,673